Brazilian patent granted for Therakind novel dry powder nasal device DriDose®
2nd December 2020 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, today announces that the Brazilian Patent Office has granted approval for the patent application for DriDose®, Therakind’s novel dry powder nasal device.
DriDose® is a Dry Powder Intranasal Device for non-invasive and painless delivery of a dry powder drug formulation. Therakind’s products are specially designed to improve adherence, particularly in difficult-to-treat patient groups. DriDose® is easy to use with no specialist training or sterile technique required in a single-handed operation and can be used by the physician, care-giver or patient themselves, and provides multiple market opportunities. The device can be used on unconscious patients as no active inhaling technique is required and its dry powder formulation enables a long shelf life.
Susan Conroy, CEO of Therakind, said:
“This patent is a key step in the building of our patent portfolio for our DriDose® nasal device. With three Therakind products already on the market, we have a tried and tested strategy to partner our products to ensure the widest outreach possible to patients and the Brazilian market offers an additional out-licensing/distribution opportunity. We believe that DriDose® has the potential to offer a new innovative delivery solution to improve patient adherence in treatment regimens.”
For those interested in partnering DriDose® with Therakind, please contact us on bd@therakind.com
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
